- Home
- EDIT vs JPI Comparison
EDIT vs JPI Comparison
Compare EDIT & JPI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDIT
- JPI
- Stock Information
- Founded
- EDIT 2013
- JPI 2012
- Country
- EDIT United States
- JPI United States
- Employees
- EDIT N/A
- JPI N/A
- Industry
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- JPI Finance Companies
- Sector
- EDIT Health Care
- JPI Finance
- Exchange
- EDIT Nasdaq
- JPI Nasdaq
- Market Cap
- EDIT 241.9M
- JPI 288.1M
- IPO Year
- EDIT 2016
- JPI N/A
- Fundamental
- Price
- EDIT $2.69
- JPI $20.70
- Analyst Decision
- EDIT Buy
- JPI
- Analyst Count
- EDIT 12
- JPI 0
- Target Price
- EDIT $5.40
- JPI N/A
- AVG Volume (30 Days)
- EDIT 1.3M
- JPI 54.7K
- Earning Date
- EDIT 11-03-2025
- JPI 01-01-0001
- Dividend Yield
- EDIT N/A
- JPI 6.15%
- EPS Growth
- EDIT N/A
- JPI N/A
- EPS
- EDIT N/A
- JPI N/A
- Revenue
- EDIT $38,901,000.00
- JPI N/A
- Revenue This Year
- EDIT N/A
- JPI N/A
- Revenue Next Year
- EDIT N/A
- JPI N/A
- P/E Ratio
- EDIT N/A
- JPI N/A
- Revenue Growth
- EDIT N/A
- JPI N/A
- 52 Week Low
- EDIT $0.91
- JPI $16.02
- 52 Week High
- EDIT $4.12
- JPI $19.12
- Technical
- Relative Strength Index (RSI)
- EDIT 51.07
- JPI 66.91
- Support Level
- EDIT $2.56
- JPI $20.15
- Resistance Level
- EDIT $2.84
- JPI $20.70
- Average True Range (ATR)
- EDIT 0.17
- JPI 0.15
- MACD
- EDIT 0.00
- JPI 0.05
- Stochastic Oscillator
- EDIT 58.82
- JPI 93.22
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
About JPI Nuveen Preferred and Income Term Fund of Beneficial Interest
Nuveen Preferred and Income Term Fund is a closed-end management investment company. Its investment objective is to provide a high level of current income and total return. The company's products include mutual funds, closed-end funds, Exchange-traded funds, Multi-asset model portfolios, and others.